vs
Side-by-side financial comparison of Iterum Therapeutics plc (ITRM) and Hyperliquid Strategies Inc (PURR). Click either name above to swap in a different company.
Hyperliquid Strategies Inc is the larger business by last-quarter revenue ($500.0K vs $390.0K, roughly 1.3× Iterum Therapeutics plc). Iterum Therapeutics plc runs the higher net margin — -2302.3% vs -60892.6%, a 58590.3% gap on every dollar of revenue.
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing innovative anti-infective therapies to treat infections caused by multi-drug resistant bacteria. Its lead product candidate targets indications including community-acquired bacterial pneumonia and complicated urinary tract infections, addressing unmet medical needs across global healthcare markets.
ITRM vs PURR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $390.0K | $500.0K |
| Net Profit | $-9.0M | $-304.5M |
| Gross Margin | — | — |
| Operating Margin | -1982.3% | -57509.2% |
| Net Margin | -2302.3% | -60892.6% |
| Revenue YoY | — | — |
| Net Profit YoY | -47.3% | — |
| EPS (diluted) | $-0.20 | $-7.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $500.0K | ||
| Q3 25 | $390.0K | — |
| Q4 25 | — | $-304.5M | ||
| Q3 25 | $-9.0M | — |
| Q4 25 | — | -57509.2% | ||
| Q3 25 | -1982.3% | — |
| Q4 25 | — | -60892.6% | ||
| Q3 25 | -2302.3% | — |
| Q4 25 | — | $-7.43 | ||
| Q3 25 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $281.9M |
| Total DebtLower is stronger | $20.0M | — |
| Stockholders' EquityBook value | $-7.4M | $589.8M |
| Total Assets | $32.5M | $616.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $281.9M | ||
| Q3 25 | $11.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | $20.0M | — |
| Q4 25 | — | $589.8M | ||
| Q3 25 | $-7.4M | — |
| Q4 25 | — | $616.6M | ||
| Q3 25 | $32.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | — |
| Free Cash FlowOCF − Capex | $-7.5M | — |
| FCF MarginFCF / Revenue | -1912.6% | — |
| Capex IntensityCapex / Revenue | 3.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $-7.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-7.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | -1912.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
